Table 5.

Overall survival in phase III trials of first-line platinum/fluoropyrimidine-based regimens in advanced gastric cancer

References	Region/country	Enrollment period	Treatment	No. of patients	Median overall survival, months
Kim et al. [24]	Korea	1986–1990	FP	103	8.5
Vanhoefer et al. [25]	Europe	1991–1995	FP	134	7.2
Ohtsu et al. [26]	Japan	1992–1997	FP	105	7.1
Van Cutsem et al. [27]	International	1999–2003	FP	230	8.6
Dank et al. [28]	International	2000–2002	FP	165	8.7
Cunningham et al. [29]	UK/Australia	2000–2005	EPF	263	9.9
			EPC	250	9.9
			EOF	245	9.3
			EOC	244	11.2
Koizumi et al. [30]	Japan	2002–2004	SP	148	13.0
Kang et al. [31]	International	2003–2005	FP	156	8.9
			CP	160	10.4
Ajani et al. [32]	USA/Europe/South America	2005–2007	SP	527	8.6
			FP	526	7.9
Ohtsu et al. [4]	International	2007–2008	CP	387	10.1
Lordick et al. [33]	International	2008–2010	CP	455	10.7
Waddell et al. [34]	UK	2008–2011	EOC	275	11.3
Kim et al. [35]	Korea	2009–2012	CP	124	11.5
Shen et al. [36]	China	2009–2010	CP	102	11.4
Yamada et al. [37]	Japan	2010–2011	SP	324	13.1
			SO	318	14.1

Only data for the platinum/fluoropyrimidine-containing study arms are shown

C capecitabine, E epirubicin, F 5-fluorouracil, O oxaliplatin, P cisplatin, S S-1